Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study
Authors:
- Ewout J HoornEHEwout J Hoorn
- Esther MeijerEMEsther Meijer
- the DIPAK ConsortiumTCthe DIPAK Consortium
Open Access
- 5 November 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 36 (10) , 1828-1836
Abstract
In autosomal dominant polycystic kidney disease (ADPKD), hypertension is prevalent and cardiovascular events are the main cause of death. Thiazide diuretics are often prescribed as second-line antihypertensives, on top of renin–angiotensin–aldosterone system (RAAS) blockade. There is a concern, however, that diuretics may increase vasopressin concentration and RAAS activity, thereby worsening disease progression in ADPKD. We aimed to investigate the validity of these suggestions. We analysed an observational cohort of 533 ADPKD patients. Plasma copeptin (surrogate for vasopressin), aldosterone and renin were measured by enzyme-linked immunosorbent assay and radioimmunoassay, respectively. Linear mixed models were used to assess the association of thiazide use with estimated glomerular filtration rate (eGFR) decline and Cox proportional hazards models for the association with the composite kidney endpoint of incident end-stage kidney disease, 40% eGFR decline or death. A total of 23% of participants (n = 125) used thiazide diuretics at baseline. Compared with non-users, thiazide users were older, a larger proportion was male, they had lower eGFRs and similar blood pressure under more antihypertensives. Plasma copeptin was higher, but this difference disappeared after adjustment for age and sex. Both renin and aldosterone were higher in thiazide users. There was no difference between thiazide users and non-users in the rate of eGFR decline {difference −0.35 mL/min/1.73 m2 per year [95% confidence interval (CI) −0.83 to –0.14], P = 0.2} during 3.9 years of follow-up (interquartile range 2.5–4.9). This did not change after adjustment for potential confounders [difference final model: 0.08 mL/min/1.73 m2 per year [95% CI −0.46 to –0.62], P = 0.8). In the crude model, thiazide use was associated with a higher incidence of the composite kidney endpoint [hazard ratio (HR) 1.53 (95% CI 1.05–2.23), P = 0.03]. However, this association lost significance after adjustment for age and sex and remained unassociated after adjustment for additional confounders [final model: HR 0.80 (95% CI 0.50–1.29), P = 0.4]. These data do not show that thiazide diuretics have a detrimental effect on the rate of disease progression in ADPKD and suggest that these drugs can be prescribed as second-line antihypertensives.Keywords
Funding Information
- The DIPAK Consortium
- Dutch Kidney Foundation (CP10.12, CP15.01)
- Dutch government (LSHM15018)
- Ipsen
- Otsuka Pharmaceuticals
- Dutch Kidney Foundation (18OKG04)
This publication has 32 references indexed in Scilit:
- 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of HypertensionJournal Of Hypertension, 2018
- Recent Advances in the Management of Autosomal Dominant Polycystic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2018
- First-line drugs for hypertensionCochrane Database of Systematic Reviews, 2018
- Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016American Journal of Kidney Diseases, 2016
- Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceKidney International, 2015
- Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal diseaseNephrology Dialysis Transplantation, 2011
- Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of LosartanJournal of the American Society of Nephrology, 2008
- Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan, a Non-Peptide AVP Antagonist, and Furosemide or HydrochlorothiazideJournal of Cardiovascular Pharmacology, 2007
- Autosomal dominant polycystic kidney diseaseThe Lancet, 2007
- Renal structure and hypertension in autosomal dominant polycystic kidney diseaseKidney International, 1990